BioNTech continues to build on the success of the company’s mRNA COVID-19 vaccine co-developed with Pfizer, rapidly expanding its investigational pipeline to include additional infectious diseases and oncology with a first-in-class CAR-T program in solid tumors.
Maryland’s life sciences ecosystem has become a key hub along the eastern shore of the United States due to its position in infectious disease research and vaccine development and manufacturing. While the state saw an infusion of billions of dollars in government financing in the development of vaccines, Maryland’s Biotechnology Investment Incentive Tax Credit, is a tool that has been used to attract venture capital funding in the state.
OpGen Subsidiary Ares Genetics Launches AREScloud AREScloud is a new, commercial web application aimed at accelerating the analysis of sequenced clinical isolates AREScloud offers an advanced solution […]
Roche bolstered the Swiss pharma giant’s diagnostics capabilities by acquiring the company’s long-term partner, TIB Molbiol. The procurement will expand Roche’s PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new Covid-19 variants of interest.
One person in the U.S. state of Georgia died following a multi-state outbreak of melioidosis infection likely linked to imported products, health officials said on Aug. 9.
Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s Covid-19 vaccine, raised $168 million in a Series B financing round that will be used to support development of its own lead candidates in oncology and infectious disease.
One in seven cases of Covid-19 reported to the World Health Organization is a health worker and in some countries that figure rises to one in three, according to the WHO.
We are well into the global pandemic that has disrupted our professional and personal lives. This is a once in a lifetime paradigm shift – we have adjusted much of our day to day BUT where does clinical site contracting and budgeting fall?
Watertown, Massachusetts-based SQZ Biotechnologies closed on a $65 million Series D round, led by Temasek with participation from another new large, U.S.-based fund.
Med Ad News spoke with Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior Inc., about some of the barriers to patients seeking treatment for opioid use disorder, how to integrate treatment for opioid use disorder and infectious disease services, and the company’s efforts to provide treatments for those struggling with the disorder.